Key result
This Focus Issue editorial summarizes recent clinical research on the cardiovascular benefits of semaglutide in CKD, the impact of skeletal muscle adiposity, and the management of FH and Lp(a).
Why the study?
Does subcutaneous semaglutide 1 mg weekly reduce cardiovascular outcomes and death in participants with type 2 diabetes and chronic kidney disease?
Does subcutaneous semaglutide 1 mg weekly reduce cardiovascular outcomes and death in participants with type 2 diabetes and chronic kidney disease?
Answers are grounded in this paper and cite their sources.
This editorial highlights that semaglutide reduces cardiovascular events in T2D and CKD regardless of CKD severity, while also emphasizing that novel risk factors like intermuscular adiposity and obesity in familial hypercholesterolaemia independently drive cardiovascular risk.
For the podcast associated with this article, please visit https://academic.oup.com/eurheartj/pages/Podcasts. This Focus Issue on dyslipidaemias, diabetes, and metabolic disorders contains the Fast Track Clinical Research contribution ‘Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial’ by Kenneth Mahaffey from the Stanford School of Medicine in Palo Alto, CA, USA and colleagues.1 There is growing interest in glucagon-like peptide-1 receptor agonists (GLP1-RAs) and obesity.2–7 The authors note that in the FLOW trial, semaglutide reduced the risks of kidney and cardiovascular (CV) outcomes and death in participants with type 2 diabetes and chronic kidney disease (CKD). The current pre-specified analysis assessed the effects of semaglutide on CV outcomes and death by CKD severity. Participants were randomized to subcutaneous semaglutide 1 mg or placebo weekly. The main outcome was a composite of CV death, non-fatal myocardial infarction (MI), or non-fatal stroke (CV death/MI/stroke), as well as death due to any cause by baseline CKD severity. CKD was categorized by estimated glomerular filtration rate < or ≥60 mL/min/1.73 m2, urine albumin-to-creatinine ratio < or ≥300 mg/g, or Kidney Disease Improving Global Outcomes (KDIGO) risk classification. A total of >3500 patients were randomized, with a median follow-up of 3.4 years. Low/moderate KDIGO risk was present in 7% of patients, while 25% had high and 68% had very high KDIGO risk. Semaglutide reduced CV death/MI/stroke by 18% (hazard ratio [HR] 0.82; P = .03), with consistency across estimated glomerular filtration rate categories, urine albumin-to-creatinine ratio levels, and KDIGO risk classification (all P-interaction > .13). Death due to any cause was reduced by 20% (HR 0.80; P = .01), with consistency across estimated glomerular filtration rate categories and KDIGO risk class (P-interaction .21 and .23, respectively). Mahaffey et al. conclude that semaglutide significantly reduces the risk of CV death/MI/stroke regardless of baseline CKD severity in participants with type 2 diabetes. The contribution is accompanied by an Editorial by Subodh Verma from the University of Toronto in Canada, Francesco Cosentino from the Karolinska Institute and Karolinska University Hospital in Sweden, and Mikhail N. Kosiborod from the University of Missouri-Kansas City in Missouri, USA.8 The authors note that in the ever-evolving and growing landscape of CV, kidney, and metabolic disease management, the pluripotent effects of semaglutide are redefining our approach to protecting the heart, kidneys, and beyond. As the demonstrated benefits of semaglutide continue to unfold across a spectrum of conditions, these data not only challenge the boundaries of current medical paradigms but also demand a rethinking of how we should use such powerful tools in the fight against chronic diseases. The question now is not whether semaglutide should be part of the treatment arsenal, but rather how quickly we can integrate this agent (and other emerging and future incretin-based therapies) into clinical practice to save lives and improve outcomes. At the end of the day, knowledge can only be useful if it is put into practice! Intermuscular adiposity, a novel ectopic fat depot, is associated with coronary microvascular dysfunction independently of body mass index and other conventional risk factors, and modifies its effect on adverse cardiovascular outcomes in patients with cardiometabolic disease. BMI, body mass index; CMD, coronary microvascular dysfunction; CT, computed tomography; INOCA, ischaemia and no obstructive coronary artery disease; MACE, major adverse cardiovascular event; PET, positron emission tomography9 Skeletal muscle (SM) fat infiltration, or intermuscular adipose tissue (IMAT), reflects muscle quality and is associated with inflammation, a key determinant in cardiometabolic disease. Coronary flow reserve (CFR), a marker of coronary microvascular dysfunction (CMD), is independently associated with body mass index (BMI), inflammation, and risk of heart failure, myocardial infarction, and death. In a Clinical Research article entitled ‘Skeletal muscle adiposity, coronary microvascular dysfunction, and adverse cardiovascular outcomes’, Ana Carolina do Souza from Harvard Medical School in Boston, MA, USA, and colleagues point out that the relationship between SM quality, CMD, and CV outcomes is not known.9 Consecutive patients (n = 669) undergoing evaluation for coronary artery disease with cardiac stress positron emission tomography demonstrating normal perfusion and preserved left ventricular ejection fraction were followed over a median of 6 years for major adverse cardiovascular events (MACE), including death and hospitalization for myocardial infarction or heart failure. CFR was calculated as stress/rest myocardial blood flow. Subcutaneous adipose tissue (SAT), SM, and IMAT areas (cm2) were obtained from simultaneous PET attenuation correction computed tomography using semi-automated segmentation at the 12th thoracic vertebra level. Median age was 63 years, 70% were female, and 46% were non-white. Nearly half of patients were obese, and BMI correlated highly with SAT and IMAT (P < .001), and moderately with SM (P < .001). Decreased SM and increased IMAT, but not BMI or SAT, remained independently associated with decreased CFR (adjusted P = .03 and P = .04, respectively). In adjusted analyses, both lower CFR and higher IMAT were associated with increased MACE (HR 1.78 and 1.53, adjusted P = .002 and P < .0001, respectively), while higher SM and SAT were protective (HR 0.89 and 0.94, adjusted P = .01 and P = .003, respectively). Every 1% increase in fatty muscle fraction (IMAT/[SM + IMAT]) conferred an independent 2% increased odds of CMD and a 7% increased risk of MACE (Figure 1). The authors conclude that increased IMAT is associated with CMD and MACE independently of BMI and conventional risk factors. The presence of CMD and SM fat infiltration identifies a novel at-risk cardiometabolic phenotype. The contribution is accompanied by an Editorial by Ranil de Silva and Kevin Cheng from Imperial College London in the UK.10 The authors conclude that the data presented by Souza et al. are intriguing and, importantly, further highlight patients with CMD as a population of patients at increased clinical risk. Their work should stimulate further investigation into establishing the added value of markers of adiposity to conventional and emerging cardiac risk stratification to identify those patients who may benefit prognostically from targeted cardiometabolic interventions. Overweight and obesity are common in patients with heterozygous familial hypercholesterolaemia and are associated with higher LDL cholesterol and greater risk of atherosclerotic cardiovascular disease, independent of lipid-lowering medication. BMI, body mass index; CI, confidence interval; HDL-C, HDL cholesterol; LDL-C, LDL-cholesterol; OR, odds ratio11 In a Clinical Research article entitled ‘Overweight, obesity, and cardiovascular disease in heterozygous familial hypercholesterolaemia: the EAS FH Studies Collaboration registry’, Amany Elshorbagy from Imperial College London in the UK, and colleagues note that overweight and obesity are modifiable risk factors for atherosclerotic cardiovascular disease (ASCVD) in the general population, but their prevalence in individuals with heterozygous familial hypercholesterolaemia (HeFH) and whether they confer additional risk of ASCVD independent of LDL cholesterol (LDL-C) remains unclear.11 A cross-sectional analysis was conducted in ∼35 500 patients with HeFH across 50 countries in the EAS FH Studies Collaboration registry. Prevalence of World Health Organization-defined BMI categories was investigated in adults and children/adolescents, together with their association with prevalent ASCVD. Globally, 52% of adults and 27% of children with HeFH were overweight or obese, with the highest prevalence noted in Northern Africa/Western Asia. A higher overweight/obesity prevalence was found in non-high-income vs. high-income countries. Median age at FH diagnosis in adults with obesity was 9 years older than in normal weight adults. Obesity was associated with a more atherogenic lipid profile independent of lipid-lowering medication. Prevalence of coronary artery disease increased progressively across BMI categories in both children and adults. Compared with normal weight, obesity was associated with higher odds of coronary artery disease in children (odds ratio [OR] 9.28, adjusted for age, sex, lipids, and lipid-lowering medication) and coronary artery disease and stroke in adults (OR 2.35 and 1.65, respectively), but less consistently with peripheral artery disease. Adjusting for diabetes, hypertension, and smoking modestly attenuated the associations (Figure 2). Elshorbagy and colleagues conclude that overweight and obesity are common in patients with HeFH and contribute to ASCVD risk from childhood, independent of LDL-C and lipid-lowering medication. Sustained body weight management is needed to reduce the risk of ASCVD in HeFH. The contribution is accompanied by an Editorial by Jean-Pierre Després from the Université Laval in Québec, Canada.12 The authors note that the study by Elshorbagy et al. provides a striking example of the power of registries. Extension of this worldwide platform to include cardiometabolic imaging and lifestyle data should provide a wealth of information relevant to patients living with HeFH and to health professionals aiming at the optimal management of this condition. Familial hypercholesterolaemia leads to lifelong elevated LDL-C with increased risk of coronary heart disease and premature death, and is therefore an important therapeutic target.13–17 In a Clinical Research article entitled ‘Ages at coronary heart disease and death in familial hypercholesterolaemia: a Danish nationwide study spanning 44 years’, Jacob Reeh from the Copenhagen University Hospital-Herlev and Gentofte in Herlev, Denmark, and colleagues indicate that it is unknown whether the prognosis for individuals with FH has improved over the past four decades as registration of this condition has been limited worldwide.18 However, in Danish nationwide registries, modified International Classification of Diseases (ICD) coding has allowed such registration since 1978. From nationwide registries, all Danish residents were included in a retrospective cohort study. Inclusion and follow-up were from 1978 to 2021. Individuals diagnosed with FH were identified, and trends over time were examined for age at death and age at coronary heart disease. During follow-up for those with (n = 10 199) or without (n = 9 174 926) FH, 27% and 27% died and 34% and 9% experienced coronary heart disease, respectively. Age at death was 22 years younger in 1978 (P < .001) but similar in 2021 (P = .16) in individuals with vs. without FH. The corresponding age at coronary heart disease was 20 years younger in 1978 (P < .001), but it was still 7 years younger in 2021 (P < .001) in individuals with vs. without FH. These results were similar in women and men and in a matched analysis by sex, ethnicity, and time of birth. The authors conclude that nationwide from 1978 to 2021 in Denmark, normalization of age at death but not age at coronary heart disease is observed for individuals diagnosed with FH. The contribution is accompanied by an Editorial by Vera Bittner from the University of Alabama at Birmingham in Alabama, USA.19 Bittner highlights that based on these data, current dyslipidaemia guidelines suggest starting statins as early as age 6–10 years among children with FH, and recommend intensive statin therapy in adults, with LDL-C goals stratified by CV risk. Delays in diagnosis of FH, delays in treatment, and progression to clinical coronary heart disease in middle age persist today. Clinicians world-wide should heed recent calls to action to reduce the clinical and public health burden of FH in children and adults through implementation of robust screening and early treatment programmes. Lipoprotein(a) [Lp(a)] is in important cardiovascular risk factor.20–22 In a Rapid Communications article entitled ‘Within-person stability of lipoprotein(a) concentration’, Jonas Ghouse from the Copenhagen University Hospital in Denmark, and colleagues remind us that given the strong genetic influence on Lp(a) concentrations, a single measurement throughout the course of life has been suggested. Here, they evaluate the temporal stability of Lp(a) as a function of baseline Lp(a) levels.23 In this analysis, the authors enrolled ∼12 200 participants with baseline and follow-up Lp(a) measurements. Median Lp(a) was 21.0 nmol/L at baseline, increasing to 22.4 nmol/L at follow-up. The median time between successive measurements was 4.4 years. The overall correlation was strong between the two measurements (Spearman r = 0.94, P < .0001) but varied by baseline Lp(a) levels. For individuals with Lp(a) < 75 nmol/L, the correlation was strong (Spearman r = 0.90, P < .0001). However, with higher baseline levels, the correlation deteriorated, with an r of 0.50 (P < .0001) for levels between 75 and 125 nmol/L, and an r of 0.39 (P < .0001) for higher reference values (125–189 nmol/L). The authors conclude that while a single measurement may suffice for those with Lp(a) < 75 nmol/L or >189 nmol/L, individuals with higher values may benefit from repeat assessments to avoid misclassification. Furthermore, with the potential advent of novel Lp(a)-lowering therapies, accurate risk stratification and identification of treatment-eligible individuals become increasingly important. In a second Rapid Communications article entitled ‘Olpasiran lowering of lipoprotein(a) according to baseline levels: insights from the OCEAN(a)-DOSE study’, Gurleen Kaur from Brigham and Women’s Hospital and Harvard Medical School in Boston, MA, USA, and colleagues remind us that Lp(a) is a CV risk factor. It remains unclear, however, how much of a reduction in Lp(a) may be required to translate into meaningful clinical benefit.24 Olpasiran is a small interfering RNA that reduced Lp(a) by >95% at doses ≥75 mg when administered every 12 weeks in patients with ASCVD. Currently, it is not fully understood whether the efficacy of olpasiran varies as a function of baseline Lp(a). OCEAN(a)-DOSE was a multicentre, randomized, double-blind, placebo-controlled trial that enrolled 281 patients with a history of ASCVD and Lp(a) concentration >150 nmol/L. Patients were randomized to one of four doses of olpasiran (10 mg every 12 weeks [Q12W], 75 mg Q12W, 225 mg Q12W, or 225 mg Q24W) vs. matching placebo, administered subcutaneously. In this pre-specified analysis, the authors assessed both the percentage and the absolute change in Lp(a) at week 36 as a function of baseline Lp(a) concentration. The percentage reduction in Lp(a) with higher doses of olpasiran was independent of the baseline value. Very low values of Lp(a) were achieved for most patients, irrespective of baseline values, with all patients achieving Lp(a) values <75 nmol/L (below the EAS-proposed ‘grey zone’) at higher doses and ∼80% achieving essentially typical values that are below the Western overall population median. The authors conclude that these findings are particularly relevant given that the clinical benefit of Lp(a)-lowering therapies is postulated to depend on the magnitude of absolute reduction in Lp(a). The issue is also complemented by two Discussion Forum contributions. In a commentary entitled ‘Deep learning for cardiac abnormalities in chest X-rays: performance metrics with imbalanced data and extracardiac objects’, Eisuke Kagawa from the Hiroshima City Asa Hospital in Hiroshima, Japan and colleagues comment on the recent publication ‘Deep learning to detect left ventricular structural abnormalities in chest X-rays’ by Shreyas Bhave from the Columbia University Irving Medical Center in New York, NY, USA.25,26. Bhave et al. respond in a separate comment.27 The editors hope that this issue of the European Heart Journal will be of interest to its readers. Dr. Crea reports speaker fees from Abbott, Amgen, Astra Zeneca, BMS, Chiesi, Daiichi Sankyo, Menarini outside the submitted work. With thanks to Amelia Meier-Batschelet, Johanna Huggler, and Martin Meyer for help with compilation of this article.
No takes yet. Share an insight, caveat, or question.
Filippo Crea (2025) conducted an editorial in Cardiovascular disease, familial hypercholesterolaemia, lipoprotein(a), skeletal muscle adiposity. This Focus Issue editorial summarizes recent clinical research on the cardiovascular benefits of semaglutide in CKD, the impact of skeletal muscle adiposity, and the management of FH and Lp(a).
Synapse has enriched 10 related papers. Consider them for comparative context: